Compare GSK plc (GSK) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs ProShares UltraPro QQQ ETF — how do they compare? GSK plc trades at $52.59 (market cap $101.34B), while ProShares UltraPro QQQ ETF trades at $71.46. The key difference: GSK plc pays a 3.49% dividend while ProShares UltraPro QQQ ETF pays none. Which is the better fit depends on your goals.
| GSK | TQQQ | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $61.18 | $87.22 |
52-Week Low | $36.20 | $37.89 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
TQQQ, a 3x leveraged ETF tracking the Nasdaq-100, trades at $71.23, down 5.05% amid a bearish technical signal. The fund lacks traditional valuation ratios like P/E or P/B as it is structured to deliver daily leveraged returns, not company earnings. Recent news highlights concerns over volatility and hidden costs in leveraged ETFs, with Warren Buffett criticizing the 'gambling mood' around such products (CNBC, May 2, 2026).
The outlook for TQQQ is highly volatile, offering amplified gains in bull markets but severe losses during downturns, as seen in its 81% drop in 2022. Risks include daily rebalancing costs and market volatility amplification. Investors require strong conviction in Nasdaq-100 rallies and risk tolerance for sharp drawdowns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
